Flash FinanceUS
Market closed · weekend S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · BioLife Solutions (BLFS)

BioLife Solutions sells CBS unit to Standex for about $6.1 million

Neutral Impact 2 of 5 m&a Written later

BioLife Solutions agreed to sell all shares of its wholly owned subsidiary Custom Biogenic Systems (CBS) to Standex International for an aggregate price of about $6.1 million, subject to adjustment, and the sale closed on November 14, 2024. The filing says the company also paid $2.0 million in accelerated share compensation to former employees and repaid about $1.5 million of CBS debt, and its pro forma figures show a $840,000 loss on the sale.

Key points

  • Buyer is Standex International Corporation; sale price is about $6.1 million, subject to adjustment, with closing on November 14, 2024
  • Company incurred $2.0 million in compensation expense from accelerating unvested shares for former employees who stayed with CBS
  • Company was required to repay about $1.5 million of CBS indebtedness; pro forma loss on sale of CBS is $840,000 as of September 30, 2024
  • Company will provide transition services to CBS and is bound by two-year non-compete and non-solicitation covenants

The filing

CompanyBioLife Solutions (BLFS)
Form8-K, current report
Filed with the SECNov 20, 2024, 4:39 PM ET
Accession number0001628280-24-048673

Items reported: 1.01 Material Definitive Agreement2.01 Acquisition or Disposition Completed

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 2:07 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 20, 2024.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.